Skip to Content

Savara Inc SVRA

Morningstar Rating
$5.05 −0.04 (0.79%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

SVRA is trading at a 20% premium.
Price
$5.07
Fair Value
$7.95
Uncertainty
Very High
1-Star Price
$3.35
5-Star Price
$5.19
Economic Moat
Crycg
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if SVRA is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$5.09
Day Range
$5.015.20
52-Week Range
$1.635.44
Bid/Ask
$5.00 / $5.05
Market Cap
$683.47 Mil
Volume/Avg
1.9 Mil / 1.0 Mil

Key Statistics

Price/Earnings (Normalized)
Price/Sales
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's lead program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Core
Total Number of Employees
28

Comparables

Valuation

Metric
SVRA
ICVX
HLVX
Price/Earnings (Normalized)
Price/Book Value
4.663.302.89
Price/Sales
Price/Cash Flow
Price/Earnings
SVRA
ICVX
HLVX

Financial Strength

Metric
SVRA
ICVX
HLVX
Quick Ratio
18.8817.5917.12
Current Ratio
18.9818.0617.58
Interest Coverage
−59.70
Quick Ratio
SVRA
ICVX
HLVX

Profitability

Metric
SVRA
ICVX
HLVX
Return on Assets (Normalized)
−31.68%−29.30%−30.32%
Return on Equity (Normalized)
−40.90%−31.87%−36.74%
Return on Invested Capital (Normalized)
−35.67%−34.69%−34.21%
Return on Assets
SVRA
ICVX
HLVX
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRMpxg$541.4 Bil
VRTX
Vertex Pharmaceuticals IncVtlmvn$108.6 Bil
REGN
Regeneron Pharmaceuticals IncKkpxvg$106.0 Bil
MRNA
Moderna IncDzs$35.2 Bil
ARGX
argenx SE ADRGvl$23.7 Bil
BNTX
BioNTech SE ADRPvj$21.1 Bil
ALNY
Alnylam Pharmaceuticals IncQthxzm$19.0 Bil
BMRN
Biomarin Pharmaceutical IncZcfsrl$16.3 Bil
RPRX
Royalty Pharma PLC Class AQvkvrg$13.6 Bil
INCY
Incyte CorpRkmhcx$13.1 Bil

Sponsor Center